Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(02): 97-101
DOI: 10.1055/s-0041-1731516
Original Article: Genitourinary Cancer

Autologous Stem Cell Transplantation in Testicular Germ Cell Tumor—Preliminary Experience from a Single Center

Gangothri Selvarajan
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Perumal Kalaiyarasi Jayachandran
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Arun Kumar Rajan
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Sivashree Kesana
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Krishnarathinam Kannan
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Tenali Gnana Sagar
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Trivadi Sundaram Ganesan
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations Funding There were no external sources of funding for this project.
› Further Information
   Permissions and Reprints

Abstract

Background Germ cell tumor (GCT) of the testis is one of the highly curable solid organ malignancies. Those who experience relapse after platinum-based chemotherapy can be salvaged with systemic therapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). Complete remission can be obtained in approximately 50 to 60% of patients treated with HDCT. Our experience reports the efficacy and safety of HDCT followed by ASCT in relapsed GCT.

Methods Analysis of patient records (2012–2019) showed that three patients had received HDCT and ASCT.

Results All the three patients were treated with BEP (bleomycin, etoposide, and cisplatin) as first-line therapy. HDCT was done in Case 1 after third-line salvage and in other two patients after second-line salvage chemotherapies. High-dose carboplatin and etoposide were used as conditioning regimen. Granulocyte colony-stimulating factor was used for the mobilization of stem cells. After ASCT, complete remission was documented in all the patients. All were alive and disease-free till the last follow-up. Grade ¾ toxicities including myelosuppression, diarrhea, and mucositis were observed in all three patients.

Conclusion This is the first report from India on HDCT with ASCT in GCT. HDCT/ASCT seems to be feasible, safe, and effective in relapsed testicular GCTs.

Keywords

relapsed germ cell tumor - autologous stem cell transplant - high-dose chemotherapy - high-dose carboplatin and etoposide - long-term survival in relapsed GCT


Publication History

Article published online:
23 September 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Albers P, Albrecht W, Algaba F. et al. European Association of Urology. EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60 (02) 304-319
    CrossrefPubMedGoogle Scholar
  • 2 van MR Dijk, Steyerberg EW, Habbema JDF. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 2006; 42 (07) 820-826
    CrossrefPubMedGoogle Scholar
  • 3 Adra N, Einhorn LH. Salvage therapy for relapsed testicular cancer. Oncotarget 2017; 8 (41) 69200-69201
    CrossrefPubMedGoogle Scholar
  • 4 Lorch A, Beyer J, Bascoul-Mollevi C. et al. International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28 (33) 4906-4911
    CrossrefPubMedGoogle Scholar
  • 5 Lorch A, Bascoul-Mollevi C, Kramar A. et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29 (16) 2178-2184
    CrossrefPubMedGoogle Scholar
  • 6 Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357 (04) 340-348
    CrossrefPubMedGoogle Scholar
  • 7 Hamid AA, Markt SC, Vicier C. et al. Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. Clin Genitourin Cancer 2019; 17 (01) 58-64.e1
    CrossrefPubMedGoogle Scholar
  • 8 Shamash J, Powles T, Mutsvangwa K. et al. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol 2007; 18 (05) 925-930
    CrossrefPubMedGoogle Scholar
  • 9 Badreldin W, Krell J, Chowdhury S. et al. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach. BJU Int 2016; 117 (03) 418-423
    CrossrefPubMedGoogle Scholar
  • 10 Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M. Global incidence and outcome of testicular cancer. Clin Epidemiol 2013; 5: 417-427
    Google Scholar
  • 11 Saju SV, Radhakrishnan V, Ganesan TS. et al. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries. Med Oncol 2019; 36 (03) 28
    CrossrefPubMedGoogle Scholar
  • 12 Motzer RJ, Nichols CJ, Margolin KA. et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25 (03) 247-256
    CrossrefPubMedGoogle Scholar
  • 13 Daugaard G, Skoneczna I, Aass N. et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011; 22 (05) 1054-1061
    CrossrefPubMedGoogle Scholar
  • 14 Motzer RJ, Mazumdar M, Sheinfeld J. et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18 (06) 1173-1180
    CrossrefPubMedGoogle Scholar
  • 15 Feldman DR, Sheinfeld J, Bajorin DF. et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28 (10) 1706-1713
    CrossrefPubMedGoogle Scholar
  • 16 Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21 (22) 4100-4104
    CrossrefPubMedGoogle Scholar
  • 17 Ongoing Clinical Trials in Testicular Cancer. The TIGER Trial. Oncol Res Treat 2016; 39 (09) 553-556
    CrossrefPubMedGoogle Scholar
  • 18 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02375204. Accessed April 7, 2020
  • 19 Rick O, Bokemeyer C, Beyer J. et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 20 Selle F, Wittnebel S, Biron P. et al. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. Ann Oncol 2014; 25 (09) 1775-1782
    CrossrefPubMedGoogle Scholar
  • 21 Simonelli M, Rosti G, Banna GL, Pedrazzoli P. Italian Germ cell cancer Group (IGG), Gruppo Italiano Trapianto Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO). Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol 2012; 23 (04) 815-822
    CrossrefPubMedGoogle Scholar
  • 22 Popovic L, Matovina-Brko G, Popovic M. et al. High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells 2015; 7 (11) 1222-1232
    PubMedGoogle Scholar
  • 23 O'Carrigan B, Grimison P. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urol Oncol Semin Orig Investig. 2015; 33 (08) 343-354
    Google Scholar
  • 24 Siegert W, Beyer J, Strohscheer I. et al. The German Testicular Cancer Cooperative Study Group. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994; 12 (06) 1223-1231
    CrossrefPubMedGoogle Scholar
  • 25 Nichols CR, Andersen J, Lazarus HM. et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10 (04) 558-563
    CrossrefPubMedGoogle Scholar